scholarly journals Ovarian Cancer Biomarkers: Current Options and Future Promise

2008 ◽  
Vol 6 (8) ◽  
pp. 795-802 ◽  
Author(s):  
Christine M. Coticchia ◽  
Jiang Yang ◽  
Marsha A. Moses

As more effective, less toxic cancer drugs reach patients, the need for accurate and reliable cancer diagnostics and prognostics has become widely appreciated. Nowhere is this need more dire than in ovarian cancer; here most women are diagnosed late in disease progression. The ability to sensitively and specifically predict the presence of early disease and its status, stage, and associated therapeutic efficacy has the potential to revolutionize ovarian cancer detection and treatment. This article reviews current ovarian cancer diagnostics and prognostics and potential biomarkers that are being studied and validated. Some of the most recent molecular approaches being used to identify genes and proteins are presented, which may represent the next generation of ovarian cancer diagnostics and prognostics.

2010 ◽  
Vol 10 (2) ◽  
Author(s):  
Ronalds Macuks ◽  
Ieva Baidekalna ◽  
Julia Gritcina ◽  
Arina Avdejeva ◽  
Simona Donina

2004 ◽  
Vol 19 (4-5) ◽  
pp. 239-249 ◽  
Author(s):  
H. Robert Bergen ◽  
George Vasmatzis ◽  
William A. Cliby ◽  
Kenneth L. Johnson ◽  
Ann L. Oberg ◽  
...  

Treatment of cancer patients is greatly facilitated by detection of the cancer prior to metastasis. One of the obstacles to early cancer detection is the lack of availability of biomarkers with sufficient specificity. With modern differential proteomic techniques, the potential exists to identify high specificity cancer biomarkers. We have delineated a set of protocols for the isolation and identification of serum biomarkers for ovarian cancer that exist in the low molecular weight serum fraction. After isolation of the low molecular weight fraction by ultrafiltration, the potential biomarkers are separated by reversed phase nano liquid chromatography. Detection via TOF or FT-ICR yields a data set for each sample. We compared stage III/IV ovarian cancer serum with postmenopausal age-matched controls. Using bioinformatics tools developed at Mayo, we normalized each sample for intensity and chromatographic alignment. Normalized data sets are subsequently compared and potential biomarkers identified. Several candidate biomarkers were found. One of these contains the sequence of fibrinopeptide-A known to be elevated in many types of cancer including ovarian cancer. The protocols utilized will be examined and would be applicable to a wide variety of cancers or disease states.


2012 ◽  
Vol 5 (5) ◽  
pp. 706-716 ◽  
Author(s):  
Archana Raamanathan ◽  
Glennon W. Simmons ◽  
Nicolaos Christodoulides ◽  
Pierre N. Floriano ◽  
Wieslaw B. Furmaga ◽  
...  

2007 ◽  
Vol 6 (7) ◽  
pp. 2509-2517 ◽  
Author(s):  
Ramila Philip ◽  
Sidhartha Murthy ◽  
Jonathan Krakover ◽  
Gomathinayagam Sinnathamby ◽  
Jennifer Zerfass ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document